The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Jan. 24, 6:31 PM

Slide #2. Autolus Therapeutics plc Secondary Offering

Company: Autolus Therapeutics plc (NASDAQ:AUTL)
Date announced: 1/22/2020
Shares Offered: 7,250,000
Date of Pricing: 1/22/2020
Price Per Share: $11.00
Secondary Offering Details: Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public offering in the United States of 7,250,000 American Depositary Shares ("ADSs") representing 7,250,000 ordinary shares at a public offering price of $11.00 per ADS, for total gross proceeds of approximately $80.0 million. All ADSs sold in the offering were offered by Autolus. In addition, Autolus has granted the underwriters a 30-day option to purchase up to an additional 1,087,500 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on January 27, 2020, subject to customary closing conditions.

Autolus Therapeutics is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using Co.'s broad suite of proprietary and modular T cell programming technologies, Co. is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells.
Open the AUTL Page at The Online Investor »

Company Name: 
Autolus Therapeutics PLC
Number of ETFs Holding AUTL: 
Total Market Value Held by ETFs: 

Open the AUTL Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Strong Buy (3.80 out of 4)
74th percentile
(ranked higher than approx. 74% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page |

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.